Proatherogenic modification of LDL by surface-bound myeloperoxidase

Area of Science:

• Biochemistry
• Immunology
• Cardiovascular Research

Background:

• Myeloperoxidase (MPO) is implicated in the oxidative modification of low-density lipoproteins (LDL).
• MPO binds to LDL, and this interaction is crucial for LDL's proatherogenic properties.
• The catalytic activity of MPO can be modulated by various factors.

Purpose of the Study:

• To investigate the impact of a specific peptide (apoB-100 fragment 445-456) and MPO inhibitors (ceruloplasmin, ABAH, thiocyanate) on cholesterol accumulation in macrophages.
• To determine how MPO-dependent LDL modification affects monocytes/macrophages.
• To explore the anti-atherogenic potential of the peptide and MPO modulators.

Main Methods:

• Incubation of LDL with MPO under various conditions (H2O2, halides).
• Treatment of monocytes/macrophages with modified LDL in the presence of the peptide or MPO inhibitors.
• Assessment of cholesterol and cholesteryl ester accumulation in cells.
• Evaluation of MPO and modified LDL uptake by monocytes/macrophages.

Main Results:

• MPO-induced LDL modification is more proatherogenic than exogenous reactive halogen species.
• The peptide EQIQDDCTGDED prevents MPO-LDL interaction, reducing modified LDL and MPO uptake by monocytes/macrophages.
• The peptide, ceruloplasmin, ABAH, and thiocyanate significantly reduce intracellular cholesterol accumulation.

Conclusions:

• MPO binding to LDL is essential for its proatherogenic modification.
• The peptide EQIQDDCTGDED and MPO inhibitors exhibit anti-atherogenic effects by mitigating MPO-driven LDL damage and subsequent cholesterol accumulation.
• Targeting the MPO-LDL interaction presents a potential therapeutic strategy against atherosclerosis.